Studies how well hormone treatment works in advanced womb cancer
Studies tumor tissue taken before hormone treatment in advanced or returning endometrial cancer.
Plain-language title generated from the registry record
Registry title: PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Key facts
- Where
- Nijmegen, NetherlandsSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 110 years old?
Source: NCT03621904, who can take part
Where in Netherlands
- RadboudumcNijmegen, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Radboud University Medical Center
- Trial code
- NCT03621904
- Record updated
- 18 January 2023
- Original description
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapyRead full original descriptionShow less
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
Inclusion: Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer; All histologic types of endometrial carcinoma; Planned treatment with any type of hormonal therapy; Biopsy taken within 120 days prior to start of hormonal therapy with no intercurrent therapy between biopsy and start of hormonal therapy.
Exclusion: Adjuvant hormonal therapy started following complete resection of endometrial carcinoma; Synchronous use of hormonal therapy for other indications; Endometrial sarcoma or endometrial stroma cell sarcoma.